A multicenter, cooperative prospective, nonrandomized, open-label, comparative study using historical controls to verify the effectiveness of simple plasma exchange therapy for patients with the most severe form ANCA associated vasculitis

A multicenter, cooperative prospective, nonrandomized, open-label, comparative study using historical controls to verify the effectiveness of simple plasma exchange therapy for patients with the most severe form ANCA associated vasculitis - Efficacy verification trial of plasma exchange therapy for the most severe form ANCA associated vasculitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031999

Enrollment

Registered

2018-04-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA associated vasculitis

Interventions

Plasma exchange Plasma exchange therapy should be performed once with 2.0 to 3.0 L and three times as one course. Nafamostat mesilate is used as an anticoagulant and fresh frozen plasma is used as a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Fulfill classification criteria for ANCA-associated vasculitis of any age 20 years or older, written in written form, either microscopic polyangiitis, polyangiitis granulomatosis, eosinophilic polyangiitis granulomatosis Patients who have newly developed or relapsed the condition that becomes the most severe type this time.

Exclusion criteria

Exclusion criteria: If there is a withdrawal of consent of research cooperation from the research subject. When the whole research is canceled. If for other reasons the researcher judges that the cancellation of research is appropriate. When adverse reactions with difficult plasma continuation therapy appear.

Design outcomes

Primary

Measure	Time frame
One year survival rate	—

Countries

Japan

Contacts

Public ContactYoshiyuki Abe

Juntendo university Department of Internal Medicine and Rheumatology

yo-abe@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026